<DOC>
	<DOCNO>NCT01469975</DOCNO>
	<brief_summary>Advanced synovial sarcoma represent unmet medical need . The gene encode frizzle homologue 10 ( FZD10 ) , 7-transmenbrane receptor , member Wnt signal receptor family , overexpressed SS undetectable normal human tissue except placenta . OncoTherapy Science Inc. develop chimeric humanize monoclonal antibody ( mAb ) FZD10 , name OTSA101 . Non-radiolabeled OTSA101 antibody weak antagonistic activity SS cell growth . However , Yttrium 90-radiolabeled OTSA101 ( OTSA101-DTPA-90Y ) show significant antitumor activity follow single intravenous injection mouse xenograft model . This first man clinical trial ( Phase I ) relapse SS patient resistant Doxorubicin ifosfamide divide 2 part . In Part 1 ( image part use OTSA101 radiolabelled Indium 111 [ 111In ] ) , biodistribution tumor uptake OTSA101-DTPA-111In follow use 111In radiotracer . In Part 2 ( therapeutic part OTSA101 radiolabelled Yttrium 90 [ 90Y ] ) , safety PK profile OTSA101-DTPA-90Y determine preliminary efficacy data collect . This first Man study allow define optimal recommend dose OTSA101-DTPA-90Y . Patients follow 1 year .</brief_summary>
	<brief_title>First Man Study Investigating Biodistribution , Safety Optimal Recommended Dose New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10</brief_title>
	<detailed_description>PART 1 : Imaging OTSA101 DTPA-111In OTSA101-DTPA-111In ( 1.5mg OTSA101-DTPA radiolabeled 185 MBq 11In ) administer intravenously ( IV ) single injection Day -28 ( D-28 ) . Patients undergo serial anterior-posterior gamma scan single photon emission compute tomography ( SPECT/CT ) 1 , 2 , 5 , 24 , 48 , 72 , 144 hour post-dosing estimate absorb radiation dose tumor , normal organ ( i.e. , liver , lung , kidney , bone marrow ) , whole body order determine OTSA101-DTPA-111In tumor uptake ( ID % /g [ % inject dose ( ID ) per gram tumor ] ) biodistribution ( ratio tumor/normal tissue estimate radiation-absorbed dose ) . PK sample perform time point additional sample D-14 D0 . A Steering Committee meeting plan end PART 1 patient . The Steering Committee evaluate case case basis Day -7 patient he/she proceed therapeutic part base tumor target , biodistribution , safety clinical assessment : - Patients expect biodistribution tumor uptake , safety concern overt sign disease progression proceed therapeutic part study validation Steering Committee . - Patients display abnormal/unexpected biodistribution OTSA101-DTPA-111In , safety concern and/or overt sign disease progression take study therapeutic plan envisage . PART 2 : Therapeutic dose OTSA101-DTPA-90Y OTSA101-DTPA-90Y administer IV single injection Day 0 ( i.e . 28 day injection OTSA101-DTPA-111In - A 1week-delay [ i.e . +7 day ] authorize plan D0 ) . Twelve ( 12 ) patient randomize PART 2 treat OTSA101-DTPA-90Y two initial dose level ( 6 patient per dose level ) : - Arm A : 1.5 mg OTSA101-DTPA radiolabeled 370MBq 90Y ( Dose level 1 ( DL1 ) - Arm B : 1.5 mg OTSA101-DTPA radiolabeled 1110 MBq 90Y ( Dose level 2 ( DL2 ) Based safety preliminary efficacy data , third dose level evaluate 6 additional patient : - Arm C : 3 mg OTSA101-DTPA radiolabeled 2220 MBq 90Y ( Dose level 3 ( DL3 ) . Such study design allow determination optimal recommend dose , surround low suboptimal dose high maximal tolerate ( possibly toxic ) dose . The first 3 patient enrol Centre Léon Bérard . Following randomization first 2 patient , accrual stop maximal period 1 month . The safety data review every 2 randomized patient . Thee benefit/risk ratio regularly review iDSMB Steering Committee ( See Section Study Committee ) . A compassionate program plan randomized patient derive clinical benefit study drug ( least stable disease acceptable tolerance ) . A maximum 4 injection per year plan . Subsequent injection perform provide eligibility criterion ( except criterion relate previous treatment ) meet day administration . All inclusion compassionate program validate Steering Committee .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>Male female patient , age ≥ 18 year . Histologically confirm progressive synovial sarcoma minimal total tumor volume 65mL time inclusion . Frozen paraffinembedded tumor sample immunohistochemical analysis mandatory registration study . Patients doxorubicin ifosfamideresistant synovial sarcoma ( defined patient progression doxorubicin ifosfamide treatment rapid progression ( i.e . within 4 month ) last dose doxorubicin ifosfamide , patient previously treat doxorubicin ifosfamide disease progression another regimen chemotherapy advanced disease ) . Patients must disease amenable surgery , radiation combine modality treatment curative intent . At least one measurable site disease define RECIST criterion 1.1 . ECOG performance status 0 , 1 , 2 . Life expectancy ≥ 3 month . Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % assessed MUGA scan ECHO screening . Normal pulmonary function Force Vital Capacity ( FVC ) least 60 % DLCO least 50 % . Adequate bone marrow , liver renal function include follow : Absolute neutrophil count ≥ 1.5 G/L , platelet count ≥ 100 G/L , hemoglobin ≥ 10 g/dL ) AST/ALT ≤ 3 x upper limit normal ( ULN ) ( ≤ 5.0 x ULN liver metastasis ) total bilirubin ≤ 1.5 x ULN ( ≤ 2.5 x ULN liver metastasis ) , Serum creatinine ≤ 1.5 x ULN creatinine clearance ≥ 50 mL/min accord Cockroft formula . Adequate contraceptive method whole duration study 12 month last study drug administration . Mandatory affiliation health insurance company . Patients must provide write informed consent study specific procedure assessment , must willing comply follow assessment procedure . Chemotherapy within last 4 week inclusion ; radiotherapy , investigational agent within 14 day 5 halflives , whichever long prior first dose study drug . Positive human antimouse antibody ( HAMA ) human antichimeric antibody ( HACA ) response . HAMA/HACA assay perform patient previously treat monoclonal antibody . Uncontrolled arterial hypertension : systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg despite appropriate therapy . Patients brain metastasis . Previous history highdose chemotherapy stem cell rescue . Chronic use immunosuppressive drug systemic corticosteroid . Previous therapy monoclonal antibody within 4 month study entry . Clinically significant abnormal ECG ( i.e . &gt; grade 1 ) inclusion . Prior history malignancy synovial sarcoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix ) unless subject free disease least 3 year . No resolution specific toxicity ( exclude alopecia ) relate prior anticancer therapy Grade ≤ 1 accord NCI CTCAE v4 . Known immediate delay hypersensitivity reaction 111In , 90Y , DTPA excipients investigational product . Psychological , familial , sociological , geographical condition would limit compliance study protocol requirement . Pregnant breastfeed woman ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>relapse refractory</keyword>
</DOC>